Long lasting insulinotropic peptides
AssigneeConjuChem, Inc.
InventorsDominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
Life of this patent
Estimating the term…
Abstract
Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
Claims14
An insulinotropic peptide modified with a reactive group which reacts with amino groups, hydroxyl groups or thiol groups on blood components to form a stable covalent bond, the insulinotropic peptide being selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO 19, SEQ ID NO:20 and SEQ ID NO:21.
A composition comprising a derivative of an insulinotropic peptide, said derivative comprising a reactive group which reacts with amino groups, hydroxyl groups or thiol groups on blood components to form stable covalent bonds wherein said reactive group is selected from the group consisting of succinimidyl and maleimido groups for use in a method of treating diabetes in a human, and wherein the insulinotropic peptide is selected from the group consisting of SEQ ID NO:16, SEQ ID NO;17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO;20, SEQ ID NO:21 and SEQ ID NO:22.
A derivative of an insulinotropic peptide, said derivative comprising a maleimido group which reacts with a thiol group on human serum albumin to form a covalent bond, the insulinotropic peptide being selected from the group consisting of SEQ ID NO:
- 16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 and SEQ ID NO:22.
A composition comprising a derivative of an insulinotropic peptide, said derivative comprising a maleimido group which reacts with a thiol group on human serum albumin to form a covalent bond for use in a method of treating diabetes in a human, the insulinotropic peptide being selected from the group consisting of SEQ ID NO:
- 16 SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 and SEQ ID NO:22.
Dependencies are inferred from the claim text.